ANAB compared with TRAX: revenue, margins and what each company keeps, and the suppliers and customers both name

ANABAnaptysbio, Inc

Mkt capRevenueRevenue

TRAXFirst Tracks Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ANABAnaptysbio, Inc

TRAXFirst Tracks Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ANAB

1 of 4at or beyond implied

Reportimpliedrealized× implied

May 13 '26±6.7%▼−4.41%×0.66

Q1 FY26±14.1%▲+14.61%×1.04

Q4 FY25±10.0%▲+9.76%×0.98

Q3 FY25±16.7%▲+3.63%×0.22

TRAX2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+5.83%—

Q2 FY26±13.3%▼−4.55%×0.34

= impliedANAB realized, solidTRAX realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedspan: ANAB 189d · TRAX 83dSource: market data

ANABAnaptysbio, Inc

46.43▲+1.87%· post 46.43

Mkt cap$1.4BRevenue$26MQ1 FY26Revenue$235MFY25

TRAXFirst Tracks Biotherapeutics, Inc.

47.90▲+5.44%· post 48.41

ClosedNov 6 '26

Mkt cap$1.7BRevenue—Revenue—

Compare

ClosedNov 6 '26

ANABAnaptysbio, Inc

TRAXFirst Tracks Biotherapeutics, Inc.

46.43▲+1.87%post 46.43

Price

47.90▲+5.44%post 48.41

$1.4B

Mkt cap

$1.7B

Q1 FY26$26M

Revenue

—

FY25$235M

Revenue

—

ANAB46.43▲+1.87%vsTRAX47.90▲+5.44%ClosedNov 6 '26